NCT01832350View on ClinicalTrials.gov

Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease

PHASE4TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 28, 2012

Primary Completion Date

December 1, 2015

Study Completion Date

December 1, 2016

Conditions
Alzheimer's DiseasePseudobulbar Affect (PBA)
Interventions
DRUG

Nuedexta (20/10)

Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.

Trial Locations (1)

85013

Barrow Neurological Institute, Phoenix

Sponsors

Collaborators (1)

Avanir Pharmaceuticals
All Listed Sponsors
collaborator

Avanir Pharmaceuticals

INDUSTRY

lead

St. Joseph's Hospital and Medical Center, Phoenix

OTHER

NCT01832350 - Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter